Subtype
High-Grade Glioma, NOS
CI-CAN-00009391Explore in graph →
75 active trials2 approved drugs11 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009391Explore in graph →
Clinical trials
173 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06161610 | Recurrent High Grade Glioma Treated by LITT(REGALITT) | recruiting | N/A | 135 | Beijing Tiantan HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06215495 | A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial | recruiting | N/A | 88 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06305910 |
| CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults |
| recruiting |
| Phase 1 |
| 24 |
| OX2 TherapeuticsINDUSTRY |
| 1 |
| Mar 12, 2024 |
| clinicaltrials |
| NCT06118723 | The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)(SUPRAMAX) | recruiting | — | 784 | Jasper GerritsenOTHER | 5 | Feb 22, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 29, 2024source: clinicaltrials